A site where you can find recommended contractors for non-clinical testing｜effical " Non-Clinical CROs and Agencies " CMIC HOLDINGS Co., Ltd.

CMIC HOLDINGS Co., Ltd.

Table of Contents

CMIC HOLDINGS Co., Ltd. leverages their experience of more than 30 years and know-how as a CRO(contract research organization) to provide customizable services to meet clients’ diverse needs. This page show-cases the key features of CMIC’s non-clinical study services, examples of disease models, and related case studies. We hope it serves as a reference when you select a CRO for non-clinical research.

Features of CMIC HOLDINGS Co., Ltd.’s Non-Clinical Study Services

High-Quality Studies

CMIC HOLDINGS Co., Ltd. conducts high-quality non-clinical studies in compliance with Good Laboratory Practice (GLP) standards. The company provides highly reliable data in pharmacodynamic and pharmacokinetic studies by evaluating the safety under strict quality control.

Extensive Experience and Expertise

With a strong track record in contract research, CMIC HOLDINGS Co., Ltd. offers flexible solutions tailored to a wide range of research needs. The company has collaborated with many pharmaceutical and biotech firms, providing extensive consulting and scientific support.

Diverse Animal Models

CMIC HOLDINGS Co., Ltd. offers a wide range of animal models for specific therapeutic areas. They have a laboratory infrastructure that allows for accurate evaluation efficacy, and new models can also be developed if requested.

3 Specialized Pre-clinical CROs for Advanced Drug Discovery

Examples of Disease Models Maintained by CMIC HOLDINGS Co., Ltd.

It is essential to go through the testing of candidate compounds in animal models that reproduce the target disease before advancing to clinical trials.

However, clinically relevant disease models may not always exist, thus there are demands for animal models with strong clinical correlation.

Below are some examples of disease models offered at Ina Research.

Allergic Rhinitis Model

Guinea pigs sensitized with OVA are used to evaluate drug effects on acute/chronic nasal reactions—such as rhinitis and nasal obstruction—induced by intranasal antigen administration, as well as on inflammatory cell infiltration in the nasal cavity.
Rats can also be used for efficacy studies on increased vascular permeability in the nasal mucosa.

Asthma Model

Guinea pigs sensitized with OVA are used to examine drug effects on acute/chronic asthmatic reactions and airway obstruction induced by antigen inhalation, as well as on inflammatory cell infiltration in the airway lumen.
Mouse models are also available to investigate airway hyperresponsiveness and airway remodeling.

Non-Clinical Study Cases by CMIC HOLDINGS Co., Ltd.

No case studies are currently listed on the official website.

Corporate Information

Backed by extensive experience in non-clinical research, CMIC HOLDINGS Co., Ltd. provides comprehensive services ranging from new drug development planning to preparation of regulatory submission documents.

Address	1-1-1 Shibaura, Minato-ku, Tokyo, Japan
Tel	03-6779-8000
Website	https://www.cmicgroup.com/

3 Recommended Contract Research Organizations for Non-Clinical Studies
— by Target goal and Expertise

In drug discovery, the quality and efficiency of non-clinical studies have a direct impact on clinical success rates, development costs, and overall length of time required in R&D. In recent years, there has been more demand for clinically relevant data, globally accepted reliability, and accurate early-stage screening. Thus, it is more important than ever to select the right CRO (Contract Research Organization) for strategic approach.
In this article, we highlight three CROs with proven technical capabilities, expertise, and long standing track records. These are our TOP 3 choices based on their capabilities and the specific target goals of the researchers for their non-clinical studies.

Pharmacology (Efficacy) Studies
Replicate unknown pathological models and
Discovery to clinically oriented drug evaluation

SMC Laboratories, Inc.

Reference: SMC Laboratories, Inc. official website (https://www.smccro-lab.com/jp/)

SMC Laboratories, Inc. has established a disease models using patented mouse technologies. The company has established proprietary pathological models—particularly in liver disease and fibrosis—and continues to expand their approach across a wide range of models in cancer, inflammation, and metabolic diseases.
From exploratory research to clinically oriented efficacy evaluation, SMC offers customized study designs, dosing strategies, and evaluation analysis tailored to each project. Their collaborative approachallows researchers to discuss and refine study plans together with SMC’s expert scientists.
With flexible small-scale study options and strong technical support, SMC Laboratories, Inc. is an ideal partner for start-ups, biotech ventures, and academic institutions alike.

Consult study design and disease model development
with SMC Laboratories, Inc.

Consult SMC Laboratories
Call us

Safety Studies
Comprehensive Safety Evaluation for FIH Applications

Labcorp Holdings Inc.
(Labcorp Drug Development)

Reference: Labcorp Holdings Inc. official website (https://jp.labcorp.com/)

Labcorp Holdings Inc. provides a fully integrated GLP testing system aligned with international regulatory standards, including FDA, EMA, and PMDA requirements. All studies are conducted under ICH-compliant quality assurance, making it ready for data submission.
The company has extensive expertise in long-term toxicity studies such as Segment I–III reproductive and carcinogenicity studies, as well as 2-year chronic toxicity assessments.
Labcorp Holdings Inc.’s comprehensive approach enables sponsors to efficiently outsource the entire preclinical package from toxicology, toxicokinetic (TK), and safety pharmacology study design to execution. This accelerates a path to First-in-Human (FIH) trials. For most of the global drug developers, this all-in-one service structure minimizes cost, risk, and expedite the time before advancing to clinical phase.

Consult Labcorp Holdings Inc.
Discuss GLP/ICH-compliant study design for your FIH submission.

To labcorp.
Call us

Pharmacokinetic (PK/PD) Studies
High-Precision Bioanalysis for Clinically Predictive PK/PD Evaluation

PhoenixBio Co., Ltd.

Source: PhoenixBio Co., Ltd. Official Website (https://phoenixbio.co.jp/)

PhoenixBio Co., Ltd.offers pharmacokinetic and hepatic metabolism studies using their proprietary PXB-mouse®, a humanized-liver chimeric mouse model. This platform enables the acquisition of data with high clinical correlation in ADME, drug–to-drug interaction studies, bridging the gap between preclinical and clinical stages.
With advanced LC-MS/MS-based bioanalysis, PhoenixBio Co., Ltd. provides aseamless workflow from plasma concentration measurement and metabolite identification to quantitative validation.
The company offersan integrated evaluation analysiscovering pharmacokinetics, hepatotoxicity, and safety with flexibility to accommodate complex modalities such as oligonucleotide and middle-molecule therapeutics. For compounds where hepatic metabolism is a development bottleneck—or where quantitative, reproducible exposure data are critical—PhoenixBio Co., Ltd. delivers unmatched analytical precision and consistency.

Consult Phoenix Bio for PK/PD analysis with a clinical focus

Phoenix Bio.
Call us